Deep-learning prioritization of metagenomic products yielded cytotoxic compounds
MetasynBGC used gene-cluster-family-guided metagenomic mining and a Chemprop graph neural network to prioritize predicted natural-product structures for synthesis. Six selected NRPS-derived compounds showed in-vitro cytotoxic activity across seven cancer cell lines, with reported IC50 values as low as 38.04 μM; compounds D and E showed cell-line-selective activity. These are in-vitro results and do not establish in-vivo efficacy or therapeutic benefit.
Technology: Chemprop graph neural network used to prioritize predicted biosynthetic products by antitumor activity
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Six synthesized NRPS-derived compounds were tested in vitro across seven cancer cell lines; the paper reports IC50 values as low as 38.04 μM and selective activity for compounds D and E.
- Still unknown: No in-vivo efficacy or clinical therapeutic benefit is established. The reported potency is limited to the tested in-vitro cancer cell-line assays.
- AI role: A Chemprop graph neural network scored PRISM-predicted biosynthetic product structures for antitumor potential; the authors jointly used predicted scores and structural feasibility to prioritize compounds for synthesis and cytotoxicity testing.
Evidence sources: https://journals.asm.org/doi/10.1128/spectrum.01098-26
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary ASM article abstract, methods and author affiliation block checked for online date, model role, synthesized compounds and measured cytotoxicity..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.